News and Announcements
IND Submission to FDA for IW-2143 (BNC210) Anti-Anxiety Drug Candidate
- Published November 28, 2012 4:21PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Bionomics Limited (ASX: BNO) (ADR: BMICY) has been advised by its licensee Ironwood Pharmaceuticals Inc that an Investigational New Drug (IND) application was submitted to the US Food and Drug Administration (FDA) for a clinical trial of anti-anxiety drug candidate IW-2143.
Ironwood intends to initiate Phase I studies with IW-2143 in healthy volunteers following the filing of the IND by the FDA. The initial Phase I US trial is designed to further assess IW-2143’s pharmacokinetics.
—–
To view the full article, please click here.